IRIX
IRIDEXCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
IRIDEX exited 2025 with its strongest quarter of the year, 16% Q4 revenue growth, 22% lower full-year opex, positive 2025 adjusted EBITDA, 2026 revenue guidance of $51 million to $53 million, and a stated goal of positive operating cash flow; at roughly $21 million market cap, that leaves meaningful upside if execution continues [#8-K-2026-03-26].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Gross-margin pressure from tariffs, manufacturing costs, and inventory dynamics could offset revenue gains.
Momentum
77
Value
36
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $1.60 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $3.00
Why
Momentum77 · Δ7d -
Value36 · Δ7d -0.0
Sentiment32 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
77
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
32
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 77.3 / Value 36.4 / Sentiment 32.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$18.28M
Beta
0.70
Shares Out
17.19M
P/E (TTM) · Derived
-2.0
P/S (TTM)
0.41
P/FCF (TTM) · Derived
-4.48
Rev YoY
+7.8%
EPS YoY
+20.7%
Gross Margin
+38.2%
Op Margin
-6.0%
Net Debt
$351K
Current Ratio
1.94
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology